Beta2-adrenergic receptor agonist

(Redirected from Beta2-adrenergic agonist)
Jump to: navigation, search

WikiDoc Resources for Beta2-adrenergic receptor agonist

Articles

Most recent articles on Beta2-adrenergic receptor agonist

Most cited articles on Beta2-adrenergic receptor agonist

Review articles on Beta2-adrenergic receptor agonist

Articles on Beta2-adrenergic receptor agonist in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Beta2-adrenergic receptor agonist

Images of Beta2-adrenergic receptor agonist

Photos of Beta2-adrenergic receptor agonist

Podcasts & MP3s on Beta2-adrenergic receptor agonist

Videos on Beta2-adrenergic receptor agonist

Evidence Based Medicine

Cochrane Collaboration on Beta2-adrenergic receptor agonist

Bandolier on Beta2-adrenergic receptor agonist

TRIP on Beta2-adrenergic receptor agonist

Clinical Trials

Ongoing Trials on Beta2-adrenergic receptor agonist at Clinical Trials.gov

Trial results on Beta2-adrenergic receptor agonist

Clinical Trials on Beta2-adrenergic receptor agonist at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Beta2-adrenergic receptor agonist

NICE Guidance on Beta2-adrenergic receptor agonist

NHS PRODIGY Guidance

FDA on Beta2-adrenergic receptor agonist

CDC on Beta2-adrenergic receptor agonist

Books

Books on Beta2-adrenergic receptor agonist

News

Beta2-adrenergic receptor agonist in the news

Be alerted to news on Beta2-adrenergic receptor agonist

News trends on Beta2-adrenergic receptor agonist

Commentary

Blogs on Beta2-adrenergic receptor agonist

Definitions

Definitions of Beta2-adrenergic receptor agonist

Patient Resources / Community

Patient resources on Beta2-adrenergic receptor agonist

Discussion groups on Beta2-adrenergic receptor agonist

Patient Handouts on Beta2-adrenergic receptor agonist

Directions to Hospitals Treating Beta2-adrenergic receptor agonist

Risk calculators and risk factors for Beta2-adrenergic receptor agonist

Healthcare Provider Resources

Symptoms of Beta2-adrenergic receptor agonist

Causes & Risk Factors for Beta2-adrenergic receptor agonist

Diagnostic studies for Beta2-adrenergic receptor agonist

Treatment of Beta2-adrenergic receptor agonist

Continuing Medical Education (CME)

CME Programs on Beta2-adrenergic receptor agonist

International

Beta2-adrenergic receptor agonist en Espanol

Beta2-adrenergic receptor agonist en Francais

Business

Beta2-adrenergic receptor agonist in the Marketplace

Patents on Beta2-adrenergic receptor agonist

Experimental / Informatics

List of terms related to Beta2-adrenergic receptor agonist

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Beta2-adrenergic receptor agonists are a class of drugs used to treat asthma and other pulmonary disease states.

Types

They can be divided into short-acting and long acting beta-adrenoceptor agonist (LABA) groups:

Short-acting beta2 agonists

Long-acting beta2 agonists

Ultra long-acting beta2 agonists

Uses

They act on the β2-adrenergic receptor, thereby causing smooth muscle relaxation resulting in dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle and release of insulin. Side effects such as insomnia, anxiety, and tremor occur in some patients. All β2 agonists are available in inhaler form (either metered-dose inhalers, which aerosolize the drug, or dry powder which can be breathed in).

Salbutamol (known as albuterol in the U.S.) also comes in a liquid form for nebulization, which is more commonly used in emergency rooms than inhalers. Salbutamol and terbutaline are also both available in oral forms.

In addition, several of these medications are available in intravenous forms including both salbutamol and terbutaline. It can be used in this form in severe cases of asthma, but more commonly it is used to suppress premature labor because it also relaxes uterine muscle, thereby inhibiting contractions.

Risks

On November 18, 2005, Food and Drug Administration (FDA) alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing (bronchospasm) in some people, and requested that manufacturers update warnings in their existing product labeling.

On June 29, 2006, Cornell University and Stanford University researchers reported that a meta-analysis they conducted found that "regularly inhaled beta-agonists (Orciprenaline/metaproterenol [Alupent], formoterol [Foradil], Fluticasone/salmeterol [Serevent, Advair] and Salbutamol/albuterol [Proventil, Ventolin, Volmax and others]) increased the risk of respiratory death more than twofold, compared with a placebo," while used to treat chronic obstructive pulmonary disease (COPD).[1]

References

  1. Ramanujan K. Common beta-agonist inhalers more than double death rate in COPD patients, Cornell and Stanford scientists assert. Chronicle Online. June 29, 2006. Available at: http://www.news.cornell.edu/stories/June06/Salpeter.COPD.kr.html. Accessed June 30, 2006.





Linked-in.jpg